Ortivus AB (LTS:0H1Q) Cyclically Adjusted Revenue per Share: kr6.29 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0H1Q Ortivus AB LTS:0H1Q
44 GF Score
Price kr5.10
GF Value kr6.51
! 3 Warning Signs
View Full Analysis

What is Ortivus AB Cyclically Adjusted Revenue per Share?

Ortivus AB LTS:0H1Q 44 Cyclically Adjusted Revenue per Share is kr6.29 as of Mar. 2026. GuruFocus rates LTS:0H1Q with a GF Score™ of 44/100 and a GF Value™ of kr6.51. The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Ortivus AB's adjusted revenue per share for the three months ended in Mar. 2026 was kr0.242. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is kr6.29 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Ortivus AB's average Cyclically Adjusted Revenue Growth Rate was -4.90% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -0.80% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 4.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Ortivus AB was 8.90% per year. The lowest was -0.80% per year. And the median was 5.30% per year.

As of today (2026-08-20), Ortivus AB's current stock price is kr5.10. Ortivus AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was kr6.29. Ortivus AB's Cyclically Adjusted PS Ratio of today is 0.81.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Ortivus AB was 3.51. The lowest was 0.56. And the median was 2.18.


Ortivus AB  (LTS:0H1Q) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Ortivus AB's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=5.10/6.29
=0.81

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Ortivus AB was 3.51. The lowest was 0.56. And the median was 2.18.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Ortivus AB Cyclically Adjusted Revenue per Share Related Terms


Ortivus AB Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Ortivus AB's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ortivus AB Cyclically Adjusted Revenue per Share Chart

Ortivus AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.09 1.89 2.77 3.78 9.22

Ortivus AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.01 4.14 4.34 9.22 6.29

LTS:0H1Q vs ISRG, BDX, MDLN: Cyclically Adjusted Revenue per Share Comparison

For the Medical Instruments & Supplies subindustry, Ortivus AB's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ortivus AB Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Ortivus AB's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Ortivus AB's Cyclically Adjusted PS Ratio falls into.


LTS:0H1Q
44GF Score
Ortivus AB LTS:0H1Q
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ortivus AB Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Ortivus AB's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.242/133.5600*133.5600
=0.242

Current CPI (Mar. 2026) = 133.5600.

Ortivus AB Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.681 101.019 0.900
201609 0.957 101.138 1.264
201612 0.702 102.022 0.919
201703 0.634 102.022 0.830
201706 0.547 102.752 0.711
201709 0.345 103.279 0.446
201712 0.505 103.793 0.650
201803 0.394 103.962 0.506
201806 0.396 104.875 0.504
201809 0.426 105.679 0.538
201812 0.461 105.912 0.581
201903 0.369 105.886 0.465
201906 0.320 106.742 0.400
201909 0.283 107.214 0.353
201912 0.321 107.766 0.398
202003 0.455 106.563 0.570
202006 0.907 107.498 1.127
202009 0.572 107.635 0.710
202012 0.493 108.296 0.608
202103 0.531 108.360 0.654
202106 0.533 108.928 0.654
202109 0.554 110.338 0.671
202112 0.510 112.486 0.606
202203 0.556 114.825 0.647
202206 0.595 118.384 0.671
202209 0.455 122.296 0.497
202212 0.753 126.365 0.796
202303 0.632 127.042 0.664
202306 0.467 129.407 0.482
202309 0.374 130.224 0.384
202312 0.438 131.912 0.443
202403 0.498 132.205 0.503
202406 0.399 132.716 0.402
202409 0.438 132.304 0.442
202412 0.480 132.987 0.482
202503 0.409 132.825 0.411
202506 0.444 133.699 0.444
202509 0.380 133.480 0.380
202512 0.258 133.390 0.258
202603 0.242 133.560 0.242

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of kr6.29 mean?
Ortivus AB (LTS:0H1Q) has a Cyclically Adjusted Revenue per Share of kr6.29 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Ortivus AB and its competitors.
Is Ortivus AB's Cyclically Adjusted Revenue per Share too high?
Ortivus AB's current Cyclically Adjusted Revenue per Share is kr6.29. Overall, Ortivus AB has a GF Score™ of 44/100, reflecting its overall financial health beyond just this single metric.
How does Ortivus AB's Cyclically Adjusted Revenue per Share compare to ISRG and BDX?
Ortivus AB's Cyclically Adjusted Revenue per Share of kr6.29 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Ortivus AB and its competitors. Ortivus AB's current Cyclically Adjusted Revenue per Share is kr6.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ortivus AB stock overvalued right now?
Ortivus AB (LTS:0H1Q) has a current Cyclically Adjusted Revenue per Share of kr6.29. The stock's GF Value™ is kr6.51, compared to a current price of kr5.10 — trading 21.7% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is kr6.29. Ortivus AB's overall GF Score™ is 44/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Ortivus AB (LTS:0H1Q), the current Cyclically Adjusted Revenue per Share is kr6.29 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ortivus AB (LTS:0H1Q) Overvalued in 2026?

Based on GuruFocus' analysis, Ortivus AB stock appears to be undervalued. The current stock price of kr5.10 is trading 21.7% below its estimated GF Value™ of kr6.51.

Key valuation signals for LTS:0H1Q:

  • Cyclically Adjusted Revenue per Share: kr6.29
  • GF Value™: kr6.51 vs. price of kr5.10 (21.7% below fair value)
  • GF Score™: 44/100 with 3 warning signs

No single metric tells the full story. See the LTS:0H1Q stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Ortivus AB Business Description

Other Exchanges ORTI B:SwedenORTI A:Sweden
Address Svardvagen 19, Danderyd, Stockholm, SWE, 182 33
Ortivus AB is a supplier of mobile solutions for modern emergency medical care. The company has developed an user-friendly solutions that supports diagnostics, increase efficiency, and deliver long-term cost savings for healthcare providers. By integrating its solutions with electronic health records, dispatch systems, and national registries, the company ensures fast and secure information management and more integrated care process. Its product portfolio includes MobiMed ePR, MobiMed Monitor, MobiMed FleetCtrl, MobiMed Life, and others.
44GF Score

Get the complete analysis for LTS:0H1Q

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr5.10
Price
kr6.51
GF Value